NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Huang Minda (HM): The TikTok ban isn’t just a prelude. Over the years, there have already been significant enforcement ...

Tech blue chips JD.com, Alibaba and Baidu lead gainers, as investors breathe a sigh of relief on potential thawing of ...

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of ...

Short selling $67.10M; Ratio 5.754% │1.34% │15.73% │2.48% FLAT GLASS (06865.HK) -0.220 (-1.903%) Short selling $3.26M; Ratio ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

ET Net News Agency, 16 January 2025] WUXI APPTEC (02359) rose 2.6% to HK$53.6, breaking above the 50-D SMA of HK$52.995. It hits an intra-day high of HK$53.85, and an intra-day l ...